Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

@article{facon2026daratumumab,
  title = {{Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis}},
  author = {Thierry Facon and Shaji K. Kumar and Robert Z. Orlowski and Nizar Bahlis and Philippe Moreau and Hartmut Goldschmidt and Supratik Basu and Cyrille Hulin and Sonja Zweegman and Katja Weisel and Aurore Perrot and Caroline Jacquet and Noopur Raje and Salomon Manier and Ajai Chari and Markus Hansson and Mohamad Mohty and Michel Delforge and Torben Plesner and Gordon Cook and Xavier Leleu and Hang Quach and Christopher P. Venner and Mourad Tiab and Margaret Macro and Laurent Frenzel and George Wang and Huiling Pei and Kasey Bolyard and Robin Carson and Fredrik Borgsten and Saad Z. Usmani},
  journal = {Leukemia},
  year = {2026},
  month = aug,
  doi = {10.1038/s41375-026-03097-9},
  url = {https://doi.org/10.1038/s41375-026-03097-9},
  note = {CC BY 4.0},
}

TY  - JOUR
TI  - Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
AU  - Thierry Facon
AU  - Shaji K. Kumar
AU  - Robert Z. Orlowski
AU  - Nizar Bahlis
AU  - Philippe Moreau
AU  - Hartmut Goldschmidt
AU  - Supratik Basu
AU  - Cyrille Hulin
AU  - Sonja Zweegman
AU  - Katja Weisel
AU  - Aurore Perrot
AU  - Caroline Jacquet
AU  - Noopur Raje
AU  - Salomon Manier
AU  - Ajai Chari
AU  - Markus Hansson
AU  - Mohamad Mohty
AU  - Michel Delforge
AU  - Torben Plesner
AU  - Gordon Cook
AU  - Xavier Leleu
AU  - Hang Quach
AU  - Christopher P. Venner
AU  - Mourad Tiab
AU  - Margaret Macro
AU  - Laurent Frenzel
AU  - George Wang
AU  - Huiling Pei
AU  - Kasey Bolyard
AU  - Robin Carson
AU  - Fredrik Borgsten
AU  - Saad Z. Usmani
PY  - 2026
DA  - 2026/08/24
JO  - Leukemia
DO  - 10.1038/s41375-026-03097-9
UR  - https://doi.org/10.1038/s41375-026-03097-9
AB  - In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. A protocol amendment (July 20, 2021) led to a long-term extension of MAIA, during which patients were followed for OS. A total of 737 patients were randomized to D-Rd (n = 368) or Rd (n = 369). At a median follow-up of 89.3 months (range, 0.0–102.2; interquartile range, 85.3–93.0), median OS was 90.3 months (95% confidence interval [CI], 80.8–not estimable [NE]) with D-Rd versus 64.1 months (56.0–70.8) with Rd (hazard ratio [HR], 0.67; 95% CI, 0.55–0.82); estimated 7-year OS rates were 53.1% (95% CI, 47.8–58.2) and 39.3% (34.1–44.5), respectively. Median time to subsequent antimyeloma treatment was not reached (95% CI, 84.1–NE) for D-Rd versus 42.4 months (33.5–50.6) for Rd (HR, 0.51; 95% CI, 0.41–0.63; P < 0.0001). Death due to adverse events occurred in 84 patients (D-Rd, n = 44/364 [12%]; Rd, n = 40/365 [11%]). With >7 years of follow-up, D-Rd demonstrated a new benchmark for median OS (7.5 years) in transplant-ineligible NDMM, further supporting frontline D-Rd use to maximize survival.
SN  - 0887-6924
SN  - 1476-5551
ER  -